In a disease perspective, our data suggest that DNA demethylation by azacytidine is modulated by DNMT1 flanking sequence preferences and our previous work provided evidence that DNA methylation changes in AML patients are related to changes in the flanking sequence preference of the DNMT3A R882H mutant24. Here, DNMT3A is linked to acute myeloid leukemia.